KR20240090616A - 안정한 항-ｉｆｎａｒ1 제형 - Google Patents

안정한 항-ｉｆｎａｒ1 제형 Download PDF

Info

Publication number
KR20240090616A
KR20240090616A KR1020247016705A KR20247016705A KR20240090616A KR 20240090616 A KR20240090616 A KR 20240090616A KR 1020247016705 A KR1020247016705 A KR 1020247016705A KR 20247016705 A KR20247016705 A KR 20247016705A KR 20240090616 A KR20240090616 A KR 20240090616A
Authority
KR
South Korea
Prior art keywords
antibody
formulation
lysine
months
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016705A
Other languages
English (en)
Korean (ko)
Inventor
로버토 데파즈
나탈리 데지저스
재레드 비
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58052002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20240090616(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20240090616A publication Critical patent/KR20240090616A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
KR1020247016705A 2015-08-19 2016-08-18 안정한 항-ｉｆｎａｒ1 제형 Pending KR20240090616A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562207164P 2015-08-19 2015-08-19
US62/207,164 2015-08-19
PCT/US2016/047506 WO2017031288A1 (en) 2015-08-19 2016-08-18 Stable anti-ifnar1 formulation
KR1020207029325A KR102669174B1 (ko) 2015-08-19 2016-08-18 안정한 항-ｉｆｎａｒ1 제형

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207029325A Division KR102669174B1 (ko) 2015-08-19 2016-08-18 안정한 항-ｉｆｎａｒ1 제형

Publications (1)

Publication Number Publication Date
KR20240090616A true KR20240090616A (ko) 2024-06-21

Family

ID=58052002

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020247016705A Pending KR20240090616A (ko) 2015-08-19 2016-08-18 안정한 항-ｉｆｎａｒ1 제형
KR1020227031079A Ceased KR20220127378A (ko) 2015-08-19 2016-08-18 안정한 항-ｉｆｎａｒ1 제형
KR1020207029325A Active KR102669174B1 (ko) 2015-08-19 2016-08-18 안정한 항-ｉｆｎａｒ1 제형
KR1020187007314A Active KR102168005B1 (ko) 2015-08-19 2016-08-18 안정한 항-ｉｆｎａｒ1 제형

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227031079A Ceased KR20220127378A (ko) 2015-08-19 2016-08-18 안정한 항-ｉｆｎａｒ1 제형
KR1020207029325A Active KR102669174B1 (ko) 2015-08-19 2016-08-18 안정한 항-ｉｆｎａｒ1 제형
KR1020187007314A Active KR102168005B1 (ko) 2015-08-19 2016-08-18 안정한 항-ｉｆｎａｒ1 제형

Country Status (23)

Country Link
US (1) US10125195B2 (https=)
EP (3) EP3769781B1 (https=)
JP (4) JP6720293B2 (https=)
KR (4) KR20240090616A (https=)
CN (1) CN107921109B (https=)
AU (3) AU2016308262C1 (https=)
CA (1) CA2995222C (https=)
CY (2) CY1123657T1 (https=)
DK (2) DK3337502T3 (https=)
ES (2) ES2818229T3 (https=)
FI (1) FI3769781T3 (https=)
HR (2) HRP20230463T1 (https=)
HU (2) HUE051862T2 (https=)
IL (1) IL257279B2 (https=)
LT (2) LT3337502T (https=)
PL (2) PL3769781T3 (https=)
PT (2) PT3337502T (https=)
RS (2) RS64263B1 (https=)
RU (1) RU2731737C2 (https=)
SG (1) SG10202106970XA (https=)
SI (2) SI3337502T1 (https=)
SM (2) SMT202000483T1 (https=)
WO (1) WO2017031288A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
EP4494712A3 (en) * 2019-11-11 2025-03-26 Astrazeneca AB Type i interferon inhibition in systemic lupus erythematosus
EP4157873A2 (en) * 2020-05-29 2023-04-05 Astrazeneca AB Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
WO2021260193A1 (en) 2020-06-25 2021-12-30 Medimmune Limited Prevention of axonal damage using antibody binding to amyloid beta 1-42
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
US20220193238A1 (en) * 2020-12-17 2022-06-23 Astrazeneca Ab Anti-il5r antibody formulations
CA3216390A1 (en) * 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of cutaneous lupus erythematous
CA3216395A1 (en) * 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN117157099A (zh) * 2021-04-23 2023-12-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
CN120392997A (zh) * 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
IL308128A (en) * 2021-05-12 2023-12-01 Astrazeneca Ab Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂
CN113527490B (zh) * 2021-07-13 2022-03-01 江苏荃信生物医药股份有限公司 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
KR20240038773A (ko) 2021-07-27 2024-03-25 아스트라제네카 아베 루푸스의 치료
JP2024536320A (ja) * 2021-10-04 2024-10-04 アストラゼネカ・アクチエボラーグ ループスの処置
EP4422674A4 (en) * 2021-10-29 2025-09-17 Intas Pharmaceuticals Ltd Stable lyophilized formulation of an anti-alpha 4beta7 antibody
WO2023155902A1 (en) * 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
WO2024009205A1 (en) * 2022-07-06 2024-01-11 Intas Pharmaceuticals Ltd. STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY
CN120344259A (zh) 2022-10-13 2025-07-18 阿斯利康(瑞典)有限公司 狼疮的治疗
AU2024277546A1 (en) 2023-05-19 2026-01-15 Astrazeneca Ab Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CL2007003583A1 (es) 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
KR20160070165A (ko) * 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
JP5933975B2 (ja) * 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CA2849192C (en) 2011-10-12 2019-09-24 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN104768578A (zh) 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
EP2997036B1 (en) 2013-05-15 2021-03-03 Medimmune Limited Purification of recombinantly produced polypeptides
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
JP2017502922A (ja) * 2013-10-29 2017-01-26 アルブミディクス アクティーゼルスカブ 抗体組成物
CA2959571A1 (en) 2014-09-03 2016-03-10 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
WO2016109822A1 (en) 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija

Also Published As

Publication number Publication date
JP2020158527A (ja) 2020-10-01
RS60773B1 (sr) 2020-10-30
HUE051862T2 (hu) 2021-03-29
IL257279B (en) 2022-12-01
HUE061985T2 (hu) 2023-09-28
EP3769781B1 (en) 2023-04-19
EP3337502A4 (en) 2019-01-23
AU2016308262B2 (en) 2020-04-30
CN107921109B (zh) 2026-04-14
JP2018523676A (ja) 2018-08-23
ES2818229T3 (es) 2021-04-09
JP2022066345A (ja) 2022-04-28
CA2995222A1 (en) 2017-02-23
ES2947488T3 (es) 2023-08-10
SI3769781T1 (sl) 2023-06-30
AU2016308262A1 (en) 2018-03-08
RU2018107725A3 (https=) 2019-10-02
US10125195B2 (en) 2018-11-13
SMT202300176T1 (it) 2023-07-20
BR112018002196A2 (pt) 2019-04-30
DK3337502T3 (da) 2020-09-14
KR102168005B1 (ko) 2020-10-21
RU2731737C2 (ru) 2020-09-08
CY1126062T1 (el) 2023-11-15
WO2017031288A1 (en) 2017-02-23
DK3769781T5 (da) 2024-08-19
LT3337502T (lt) 2020-09-25
PT3769781T (pt) 2023-06-19
EP4233892A3 (en) 2023-10-25
JP2024161043A (ja) 2024-11-15
EP3337502A1 (en) 2018-06-27
KR20180041173A (ko) 2018-04-23
AU2020203306B2 (en) 2021-09-09
KR20220127378A (ko) 2022-09-19
HRP20230463T1 (hr) 2023-07-21
US20170051066A1 (en) 2017-02-23
AU2016308262C1 (en) 2022-04-21
CA2995222C (en) 2021-07-13
AU2020203306A1 (en) 2020-06-11
AU2020203306C1 (en) 2022-03-31
RU2018107725A (ru) 2019-09-19
PL3337502T3 (pl) 2021-01-11
EP3769781A1 (en) 2021-01-27
IL257279B2 (en) 2023-04-01
SG10202106970XA (en) 2021-07-29
PL3769781T3 (pl) 2023-07-17
KR102669174B1 (ko) 2024-06-10
LT3769781T (lt) 2023-06-12
IL257279A (en) 2018-03-29
EP4233892A2 (en) 2023-08-30
PT3337502T (pt) 2020-09-23
SI3337502T1 (sl) 2020-10-30
SMT202000483T1 (it) 2020-11-10
KR20200119916A (ko) 2020-10-20
BR112018002196A8 (pt) 2021-05-04
FI3769781T3 (fi) 2023-06-07
RS64263B1 (sr) 2023-07-31
JP6720293B2 (ja) 2020-07-08
HK1256195A1 (en) 2019-09-13
CN107921109A (zh) 2018-04-17
CY1123657T1 (el) 2022-03-24
EP3337502B1 (en) 2020-06-24
DK3769781T3 (da) 2023-06-19
AU2021257915A1 (en) 2021-11-18
JP7035119B2 (ja) 2022-03-14
HRP20201297T1 (hr) 2020-11-27

Similar Documents

Publication Publication Date Title
KR102669174B1 (ko) 안정한 항-ｉｆｎａｒ1 제형
EP3060229B1 (en) Stable, aqueous antibody formulations
HK40098575A (en) Stable anti-ifnar1 formulation
HK40045114B (en) Stable anti-ifnar1 formulation
HK40045114A (en) Stable anti-ifnar1 formulation
HK1256195B (en) Stable anti-ifnar1 formulation
BR112018002196B1 (pt) Formulação de anticorpo, recipiente selado, forma farmacêutica de dosagem unitária apropriada para administração parenteral a um ser humano e uso

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240520

Application number text: 1020207029325

Filing date: 20201013

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240618

Comment text: Request for Examination of Application

PG1501 Laying open of application